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Abstract
The multi-step process of the emigration of cells from the blood stream through the vascular
endothelium into the tissue has been termed extravasation. The extravasation of leukocytes is fairly
well characterized down to the molecular level, and has been reviewed in several aspects.
Comparatively little is known about the extravasation of tumor cells, which is part of the
hematogenic metastasis formation. Although the steps of the process are basically the same in
leukocytes and tumor cells, i.e. rolling, adhesion, transmigration (diapedesis), the molecules that are
involved are different. A further important difference is that leukocyte interaction with the
endothelium changes the endothelial integrity only temporarily, whereas tumor cell interaction
leads to an irreversible damage of the endothelial architecture. Moreover, tumor cells utilize
leukocytes for their extravasation as linkers to the endothelium. Thus, metastasis formation is
indirectly susceptible to localization signals that are literally specific for the immune system. We
herein compare the extravasation of leukocytes and tumor cells with regard to the involved
receptors and the localization signals that direct the cells to certain organs and sites of the body.
Introduction
General steps of the extravasation process
The extravasation is a multi-step process of the emigration
of cells from the blood stream into the tissue. The most
prominent types of extravasating cells are leukocytes, i.e.
T lymphocytes, natural killer (NK) cells, neutrophil gran-
ulocytes and monocytes. These cells have to leave the
blood vessels in order to reach tissue sites of inflamma-
tion, infection or injury. But not only the emigrating cells,
the vascular endothelium takes actively part in the
extravasation process, too. It has to deliver certain locali-
zation signals, so that the leukocytes know where and
when to emigrate. Therefore, the endothelium changes
dynamically its architecture including receptor expression
and cell-cell contacts. In contrast to the important and
physiological extravasation of leukocytes, tumor cells are
disseminated by the circulation through the body during
hematogenic metastasis development. Akin to leukocytes,
tumor cells do not randomly leave the blood vessels, but
are guided by certain signals that are also delivered by the
vascular endothelium. Earliest observations on this have
been documented more than hundred years ago by Paget,
who regarded in his theory on breast cancer metastasis the
cancer cells as a seed that can only grow at certain sites of
the body, which he considered as the soil [1]. Balkwill and
Mantovani worded the assumption that tumor cells might
use chemokine gradients to spread around the body [2],
therefore, tumor cells and leukocytes might use similar
localization signals. The stromal cell-derived factor (SDF)-
1α is such a chemokine, which is expressed in organs that
are the first destination of breast cancer metastases [3]. We
have elaborated this hypothesis on localization signals:
ligands to G protein-coupled receptors (GPCRs), which
are chemokines and neurotransmitters as well, might
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chemotactically guide tumor cells to their destination of
metastasis formation [4].
The extravasation process is in principle divided into three
sequential steps regardless the type of cells. In the first
step, the cells slackly attach to the vascular endothelial
cells. Due to this loose interaction, the extravasating cells
are still pulled along with the blood stream, which results
in a rolling motion of the cells on the vascular surface. In
the second step, the cells tightly attach to the endothelial
cells, whereas the receptors for this interaction are differ-
ent from those involved in the rolling process. After
attachment, the previously mostly spherical cells spread
on the endothelium and actively transmigrate through the
endothelial barrier. This third step of the extravasation
process is called diapedesis.
In some descriptions of the extravasation process of leu-
kocytes, two further differentiating steps are included:
before the cells get in contact to the endothelium, they
have to move to the fringe of the blood stream, which is
termed 'margination'. There is an equilibrium between
circulating and marginated leukocytes, whereas the ratio
of these subpopulations changes under certain conditions
[5]. At the margin of the blood vessel, the flow rate is
much lower than in the centre, thus, the blood flow has a
parabolic profile of variable steepness [6]. Therefore, the
cells are slower at the fringe of the blood vessels, which
relieves rolling and adhesion. A second additional step of
the extravasation process is sometimes included between
rolling and adhesion, where the leukocytes are activated
by receptor-bound chemokines to attach tightly. This tight
attachment is mediated by integrins, which are activated
by chemokine signalling via the so-called 'inside-out' sig-
nalling. These mechanisms will be discussed in detail
below together with the characterization of the rolling
process, since these steps happen at the same time.
Types of endothelium
The structure of the vascular endothelium considerably
varies between organs and tissues of the body (Tab. 1).
This variability consequently results in differences of the
function with regard to permeability, leukocyte trafficking
and homeostasis [7]. In principle, the blood vessels are
constituted of a continuous/non-fenestrated (skin, lung,
heart, brain) endothelial monolayer, where all endothe-
lial cells are closely and continuously connected to each
other, a continuous/fenestrated (endocrine glands, intes-
tinal and gastric mucosa, glomeruli) endothelial monol-
ayer, where some minor gaps occur, especially at those
places, where three cells meet each other, or a discontinu-
ous/sinusoidal (liver) endothelial monolayer, with large
gaps that expose the underlying extracellular matrix
(ECM) [7]. Leukocytes generally leave the blood stream in
the postcapillary venules of the skin, muscle and mesen-
tery, whereas the extravasation process is different in lung,
liver and lymph nodes. In lung and liver, the cells leave
the blood stream in the microvasculature, in lymphoid
organs in the high endothelial venules (HEV), which pos-
sess a certain structure [7].
The pulmonary circulation differs fundamentally from
the systemic circulation [8]. The concentration of leuko-
cytes in pulmonary capillary blood is 35 to 100 fold
higher than in the large vessels of systemic circulation
[9,10]. As written above, extravasation occurs predomi-
nantly at postcapillary venules in the systemic circulation,
whereas in pulmonary circulation extravasation takes
place in the microvasculature [11,12]. Pulmonary capil-
laries are too small to allow rolling. Furthermore, the
involvement of selectins – an important group of adhe-
sion molecules discussed in detail below – is not clear:
there are selectin-dependent and -independent mecha-
nisms described as well [8,10]. In the liver, the hepatic
artery and portal vein drain into the hepatic sinusoids;
hepatic sinusoidal endothelial cells are discontinuous (6
to 8 percent of endothelium surface are fenestrae, which
directly expose parts of the extracellular matrix) [13]. Next
Table 1: Types of endothelium
Tissue Type of endothelium Adhesion molecules Site of extravasation
Lung non-fenestrated, continuous minor role of selectins microvasculature
Liver discontinous, fenestrated minor role of selectins, adhesion to exposed ECM microvasculature
Lymph organs HEV, plump und cuboidal constitutive expression of L-selectin ligands postcapillary venules, constitutive
Skin non-fenestrated, continuous adhesion molecules upregulated in case of inflammation postcapillary venules
Blood/brain barrier non-fenestrated, continuous no regular extravasationCell Communication and Signaling 2008, 6:10 http://www.biosignaling.com/content/6/1/10
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to the lung, the liver is the site in the body with the great-
est part of leukocyte margination. As in the lung, the
extravasation process lacks the rolling phase and endothe-
lial cells do not express selectins, which are the predomi-
nant receptors for this process [13]. The HEV of the
secondary lymph organs represent specialized postcapil-
lary venules. A special form of leukocyte trafficking was
found in these HEV of the secondary lymph organs, such
as peripheral and mesenteric lymph nodes, Peyer's
patches, appendix, and tonsils. Here, a constitutive trans-
migration of leukocytes takes place to enable leukocyte
circulation between blood and lymphatic organs, in con-
trast to normal venules, where transmigration only occurs
in case of inflammation [14,15]. Endothelial cells of the
HEVs differ from their counterparts in other organs: the
cells are plump or cuboidal instead of being flat [14,15].
Rolling
Leukocytes
Since the endothelia differ in their structural and func-
tional features as well as in the hemodynamic pattern,
there are differences in the way to recruit leukocytes [16].
In brain microvasculature, where high shear forces and
low adhesion molecule expression exist, rolling seems to
play a minor role. It was found that platelets function as a
bridge connecting leukocytes and endothelium to medi-
ate adhesion [16].
Generally, rolling of leukocytes is mainly mediated by
selectins, also named as lectin cell adhesion molecules,
which are expressed on the surface of both endothelial
cells and leukocytes (Fig. 1; Tab. 2). In contrast, tumor
cells do not express selectins, but their respective ligands.
The family of selectins comprises three members: the L-,
P- and E-selectin (CD62L, P, E). All selectins are calcium-
dependent single-chain transmembrane glycoproteins.
Rolling of leukocytes on HEV is mainly mediated by L-
selectin and its ligands. L-selectin ligands are different sul-
phated glycans, that are collectively known as peripheral
lymph node adressin [17], and are constitutively
expressed on HEV: GlyCAM-1 [18], CD34 [19], nepmucin
[20], Sgp200 [21] and others. They can function as ligands
for L-selectin when decorated with a specific carbohydrate
structure known as 6-sulfo-sialyl Lewis X (sialic acidα2–
3Galβ1–4 [Frucα1–3(sulfo-6)]GlcNAcβ1-R) [22]. This
modification is mainly mediated by the HEV restricted N-
acetylglucosamine-6-O-sulfotransferase (also known as
GST-3 or LSST) [17]. LSST is constitutively expressed in
HEV but recent studies have shown that it can be induced
in other kinds of endothelium in case of inflammatory
lesions, e.g. rheumatoid arthritis [23]. L-selectin was first
defined as a homing receptor for lymphocytes, since it is a
key regulator for the recruitment of naïve and central
memory lymphocytes to the lymph node, a process that
occurs constitutively. HEVs in mesenteric lymph nodes
also express the mucosal adressin cell adhesion molecules
(MadCAM) as a ligand for L-selectin [23], in order to
mediate rolling and adhesion via the α4β7-integrin on
leukocytes [7] (Fig. 1).
In endothelium different to HEV, additionally P-and E-
selectin regulate the rolling process of lymphocytes: P-
selectin and L-selectin lead to rolling and initial localiza-
tion of leukocytes and platelets, whereas E-selectin
enhances the subsequent recruitment of leukocytes. P-
and E-selectin both bind to PSGL-1 (P-selectin glycopro-
tein ligand-1), which is expressed on all blood lym-
phocytes, monocytes and neutrophils. P-selectin is
preformed and stored in Weibel-Palade bodies of the
endothelium and α-granules of platelets; exposure of
endothelial cells to inflammatory cytokines, histamine,
thrombin and other proinflammatory mediators leads to
a rapid upregulation of P-selectin [24].
E-selectin is expressed within the first hours after exposure
to inflammatory mediators, with the exception of the skin
and bone microvessels, where it is constitutively expressed
[25,26]. E-selectin ligands, e.g. CD43 and PSGL-1, are pro-
teins that are decorated with sialyl Lewis X (sLeX) or sialyl
Lewis A (sLeA). Decorated PSGL-1 is called cutanous lym-
phocyte antigen (CLA), that regulates skin homing of acti-
vated T cell subtypes [25]. HCELL (hematopoietic cell E-/
L-selectin ligand) is a glycoform of CD44 that is expressed
natively only on stem cells. It has the highest affinity of all
natively expressed E-selectin ligands [27].
Furthermore, we have identified N-cadherin as a molecule
involved in the rolling process of neutrophil granulocytes
on pulmonary microvasculature [28]. Cadherins are cal-
cium-dependent homophilic cell-cell adhesion molecules
in any solid tissue of the body [29]. The cadherin family
comprises several members with a distinct tissue expres-
sion patterns. Classical cadherins are the epithelial (E-),
neural (N-), placental (P-), retinal (R-) and vascular
endothelial (VE-) cadherin [29]. As the name says, N-cad-
herin is expressed in neural but also in other mesenchy-
mal and connective tissues [30]. Besides N-cadherin, only
the vascular endothelial (VE)-cadherin has yet been iden-
tified to play a role in the extravasation process of leuko-
cytes, since it is expressed in endothelial adherens
junctions [31]. However, it is so far not clear, how leuko-
cytes manage crossing of that barrier [32].
Tumor cells
Although tumor cells mimic mechanisms used by leuko-
cytes, the adhesion molecules and ligands involved in
tumor cell extravasation are somehow different suggesting
additionally or alternatively non-leukocyte-like mecha-
nisms [33]. Specific interactions between receptors of
tumor cells and ligands expressed on endothelium mayCell Communication and Signaling 2008, 6:10 http://www.biosignaling.com/content/6/1/10
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explain the distinct tropism of cancer cell subsets [25].
Several groups found tumor cells to express ligands for E-
selectin, which leads to rolling and extravasation at
endothelial sites expressing E-selectin. As written above,
these are sites of inflammation or vessels of the bones,
where E-selectin is expressed constitutively. The expres-
sion of these ligands correlates with a high potential of
bone metastasis: HCELL, which binds to L- and E-selectin,
was found on LS174 colon carcinoma cells [34], as well as
further variants of CD44 that allow L-, E- and P-selectin
interactions [35,36]. Hanley et al. [35] defined E-selectin
mediating slow, P-selectin intermediate and L-selectin fast
rolling of tumor cells. Furthermore, bone-metastatic pros-
tate carcinoma cell lines were found to express PSGL-1
and the E-selectin ligand-1 [37]. CD24, when decorated
with sLeX, also promotes hematogenic metastasis forma-
tion, but it is less efficient than PSGL-1 [38]. Recently, the
carcinoembrionic antigen (CEA), which is expressed on
Receptors involved in the rolling of leukocytes and tumor cells Figure 1
Receptors involved in the rolling of leukocytes and tumor cells. The endothelium is shown in green, leukocytes in blue 
and tumor cells in red.Cell Communication and Signaling 2008, 6:10 http://www.biosignaling.com/content/6/1/10
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colon carcinoma cells, has been reported to act as a medi-
ator for rolling on E- and L-selectin, too [39].
We have shown that N-cadherin mediates the rolling of
MDA-MB-468 human breast carcinoma cells on pulmo-
nary endothelium [28]. In addition, an other group has
described N-cadherin to be involved in the transmigration
process [40]. In conclusion, it seems that in the case of
tumor cells, there is not such a clear difference between
the receptors used for rolling, adhesion and diapedesis as
it is for leukocytes.
Furthermore, leukocytes facilitate the contact between
tumor cells and the endothelium. Leukocytes act as
bridge- or linker-cells. We have described that neutrophil
granulocytes promote the adhesion of MDA-MB-468
breast carcinoma cells to pulmonary endothelium. The
tumor cells lack β2-integrins, which are the ligand for the
intercellular adhesion molecule (ICAM)-1 on the
endothelium. Instead, the tumor cells express ICAM-1 and
adhere to neutrophil granulocytes, which then act as a
linker connecting the tumor cells to the endothelium and
thereby enable firm adhesion [28] (Fig. 1). The same
mechanism has also been described for other blood cells
and other molecules involved, e.g. the interaction of
platelets and leukocytes with tumor cells bearing ligands
for P-selectin [41-43].
Localization signals – role of GPCR ligands
Chemokines are ligands to GPCRs, which are known as
signal substances that regulate the migratory activity of
cells and chemotactically guide these cells. Chemokines
are 8 to 12 kDa peptides with highly conserved structural
elements. According to these elements they have been
divided into four subgroups [44]. More than 50 chemok-
ines and 20 chemokine receptors have been characterized
[45]. Chemokines are soluble proteins that are presented
on endothelial cells by glycosaminoglycans. These recep-
tors are not the specific chemokine-receptors, but prevent
the chemokines from rapid removal by the blood flow
[22,46]. The chemokine receptors on the leukocytes are
specifically expressed in certain subpopulations [47].
Therefore, leukocyte subsets are selectively susceptive to
various chemokines. The signal transduction of the chem-
okines receptors leads to changes of the affinity and avid-
ity of integrins on leukocytes to their specific ligands
expressed on the endothelium by the so-called 'inside-out'
signalling [48]. This activation of integrins is due to the
phosphorylation of the cytoplasmic domain of both
chains of the heterodimeric integrins [49,50], which then
leads to an integrin-mediated arrest of the cells on the
endothelium [51], as will be discussed in detail below.
Chemokines are functionally divided into two groups, the
inflammatory and the constitutive chemokines, for they
are either guiding leukocytes to sites of inflammation or
to other sites such as secondary lymph organs. For exam-
ple, CCL17/TARC (thymus- and activation-regulated
chemokine) functions as a skin-homing factor. It is pre-
sented on the skin microvasculature and induces the
adhesion of CCR4 bearing CD4+ lymphocytes [52]. HEV
express constitutively CCL21, which activates the leuko-
cyte function-associated antigen (LFA)-1 by a G protein-
mediated pathway. LFA-1 is the αLβ2-integrin, on rolling
CCR7 expressing lymphocytes. Consequently, this leads
solely to the adhesion of these cells and no other leuko-
cyte subsets transmigrate through the HEV [7,22,53]. SDF-
1α (CXCL12) is described as a very potent constitutive
chemokine for the localization of lymphocytes, homing
of stem cells to bone marrow and tumor cells [54]. SDF-
Table 2: Comparison of receptor-ligand pairs involved in the extravasation of tumor cells and leukocytes
Rolling Adhesion Diapedesis
Tumor cells PSGL-1 – E-selectin
HCELL – E-selectin
CD24 – E-selectin
CEA – E/L-selectin
N-cadherin – N-cadherin
ICAM-1/LFA-1 mediated rolling via leukocytes
α4β1/β7 – VCAM
CD44v6 – galectin-3
Lamp1/2 – galectin-3
αvβ3 – L1-CAM
N-cadherin – N-cadherin
Apoptotic mechanisms
Leukocytes PSGL-1 – E-selectin
HCELL – E-selectin
CD24 – E-selectin
L-selectin – peripheral lymph node adressin
L-selectin – MadCAM
N-cadherin – N-cadherin
LFA-1 – ICAM-1/2
Mac-1 – ICAM-1/2
LFA-1 – JAM-A
Mac-1 – JAM-C
VLA-1 – VCAM
L1-CAM – VLA-5
glycosylated proteins – galectins
paracellular:
JAM-C – JAM-B
LFA-1 – JAM-A
VLA-4 – JAM-B
Mac-1 – JAM-C
CD99 – CD99
PECAM-1 – PECAM-1
transcellular:
LFA-1 – ICAM-1
PECAM-1 – PECAM-1Cell Communication and Signaling 2008, 6:10 http://www.biosignaling.com/content/6/1/10
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1α was the first chemokine identified to play a role in the
localization of breast cancer metastases [3]. Meanwhile, it
is generally accepted that similar to leukocytes, tumor
cells use chemokines as guidance signals, too [55-57].
SDF-1α plays also a role in B16 melanoma cell adhesion
via integrins [58], and CX3CL1 (fractalkine) has been
reported to guide prostate carcinoma cells to the bone
marrow endothelium, which constitutively expresses this
chemokine [59,60].
Besides chemokines, we have suggested that neurotrans-
mitters play a role in the localization of metastases, too
[4]. Like chemokines, neurotransmitters mostly bind to
GPCRs. However, there is no common neurotransmitter
receptor, which could present neurotransmitters on the
endothelial surface. But neurotransmitters provide strong
chemotactic signals for tumor cells [61,62], and might
indirectly deliver localization signals by stimulating the
release of such signals from the endothelial cells [63]. We
have shown that the development of lymph node metas-
tases of PC-3 prostate carcinoma cells in mice increases by
norepinephrine treatment [64].
Adhesion
Leukocytes
Integrins are the main adhesion molecules of leukocytes.
During the rolling step, integrins are activated, and then
bind to their counterparts on the endothelial cells to
mediate a tight attachment (or arrest) of the leukocytes.
Integrins are single transmembrane cell adhesion mole-
cules consisting of two non-covalently associated α and β
chains. In vertebrates 18 α and 8 β subunits form 24
known  αβ dimmers, whereas β2 and β7 integrins are
exclusively expressed on leukocytes [65]. Chemokines are
the most powerful physiological activators of integrin-
mediated adhesion. Within less than a second they regu-
late integrin affinity and avidity in a cell-type specific
manner by inside-out signalling [66,67]. This signalling
induces integrins to undergo conformational changes
from a bent low-affinity state to an extended intermedi-
ate- or high-affinity state resulting in the opening of the
ligand-binding pocket [68]. However, chemokine-stimu-
lated inside-out signalling induces conformational
changes in only a fraction of integrins [51]. The intracellu-
lar signalling cascades leading from GPCR activation to
integrin activation are still incompletely understood,
since different cell types, species and integrins use differ-
ent signalling steps. A linear signal-transduction pathway
would be a simplification of the complex network
between chemoattractant-binding and integrin-adhesion
[69]. Key regulatory events are the phosphorylation of the
cytoplasmic domains [49,50], as well as binding of talin
[70].
The integrin receptor family is subdivided into 8 groups
according to the β chains. The following groups are most
widely studied: β1 (CD29) = very late activation antigen
(VLA) integrins, which mediate mainly cell-matrix inter-
actions; β2 (CD18) = leukocyte integrins, which mediate
mainly cell-cell interactions; β3 (CD61) with various
adhesive functions, and β7 integrins mediating cell-cell
interactions (Tab. 2). Those integrins that are most impor-
tant in leukocyte arrest belong to the β1 and β2 sub-
families [33,51]: the αLβ2 (lymphocyte function-
associated antigen (LFA)-1) and αMβ2 (Mac-1) are both
ligands for ICAM-1/-2 (Fig. 2), whereas αLβ2 can also
bind to the junctional adhesion molecule-A (JAM-A), and
αMβ2 to JAM-C on the endothelium, which will be
explained in detail in the diapedesis section. The α4β1
integrin VLA-4 is the ligand for the vascular cell adhesion
molecule (VCAM)-1. Neutrophil granulocytes express
VLA-4 only in case of sepsis [71]. ICAM-1/-2 (CD54/
CD102) are expressed on surface of resting endothelium
at low levels, but ICAM-1 becomes upregulated at sites of
inflammation, e.g. in response to the tumor necrosis fac-
tor (TNF)α or interleukin (IL)-1β [65]. VCAM-1 (CD106)
is also upregulated in response to inflammatory media-
tors. VCAM-1 is described as a key molecule in monocyte
recruitment to early lesions in experimental models of
atherogenesis [72,73]. Thus, on the side of the endothe-
lium, several members of the immunoglobuline (Ig)
superfamily are involved in the adhesion of leukocytes
[74]. Furthermore, integrins that are expressed on
endothelial cells are involved in leukocyte adhesion, too.
The integrins α5β1 (VLA-5) and αvβ3 on the endothelium
bind to L1-CAM, which is a molecule of the Ig superfamily
expressed on lymphocytes [33,75,76].
There is a growing body of evidence, that galectins are
involved this part of the extravasation. Galectins are
defined by their ability to recognize β-galactose because of
their conserved carbohydrate-recognition domains
(CRDs) of about 130 amino acids. Fifteen mammalian
galectins have been identified, which can be subdivided
into three groups: those with one CRD, those with two
CRDs, and chimera galectins with a tail of short tandem
repeats fused to one single CRD [77,78]. Galectins can be
secreted or, depending on the cell-type and activation
state, be localized in the nucleus, the cytoplasm or the cell
surface, where they interact with appropriately glyco-
sylated proteins [79]. The most extensively studied func-
tion of galectins is their involvement in regulation of
apoptosis (galectin-3 has anti-apoptotic function, galec-
tin-1 is a pro-apoptotic receptor) [80,81], but during the
past ten years it became evident that galectins are modu-
lators of the immune response (pro- and anti-inflamma-
tory functions) [82], as well as modulators of cell
migration, adhesion and angiogenesis [78].Cell Communication and Signaling 2008, 6:10 http://www.biosignaling.com/content/6/1/10
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Galectin-1 is a non-covalent homodimer of two single
CDR molecules, expressed in cultured endothelia of dif-
ferent origin as human aorta, umbilical vein, pulmonary
artery, and mouse liver, brain and lung [78]. The activa-
tion of endothelial cells, e.g. with lipopolysaccharides, or
tumor-conditioned media results in a rapid increase of
galectin-1 expression, and it is constitutively expressed in
tumor-associated endothelial cells [83,84]. Galectin-1 has
anti-inflammatory properties. Peretti et al. observed that
endogenous galectin-1 inhibits the adhesion of leukocytes
to the endothelium, in the case of neutrophil granulocytes
this was due to a suppression of Mac-1 upregulation [85-
87]. Thus, galectin-1 seems more to function as a signal-
ling molecule in the regulation of integrins than to act as
a classical adhesion molecule. Accordingly, the upregula-
tion of galectin-1 in tumor-associated endothelial cells is
Receptors involved in the adhesion of leukocytes and tumor cells to endothelial cells Figure 2
Receptors involved in the adhesion of leukocytes and tumor cells to endothelial cells. The endothelium is shown in 
green, leukocytes in blue and tumor cells in red.Cell Communication and Signaling 2008, 6:10 http://www.biosignaling.com/content/6/1/10
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postulated as a tumor escape mechanism from immune
response [88].
The expression of galectin-3 on endothelial cells is
reported in vitro in human umbilical vein and dermal
microvasculature as well as mouse lung, brain and liver
[78]. Galectin-3 is upregulated in endothelial cells of can-
cer tissue as found in vivo and in a murine tumor model
of hepatocellular carcinoma [89]. Nieminen et al. recently
found a role for galectin-3 in the β2 integrin-independent
adhesion of neutrophil granulocytes to lung endothelium
in case of Streptococcus infection [90].
Galectin-9 was originally identified as a chemoattractant
for eosinophil granulocytes [91]. Recently, it was identi-
fied as a receptor for the Thelper1 lymphocyte-specific cell-
surface molecule Tim-3, thus negatively regulating Thelper1
lymphocyte responses [92]. Galectin-9 is expressed in var-
ious endothelial cells but so far mainly studied in the con-
text of viral infections.
Tumor cells
As mentioned above, the expression of several integrins,
especially of the β2 subgroup, is restricted to leukocytes.
Thus, tumor cells must use some different receptors or
mechanisms for their adhesion to the endothelium, such
as utilizing leukocytes as linker cells (Fig. 1). However,
expression of the α4 integrin was demonstrated on many
different human tumors and tumor cell lines, especially
on melanoma and sarcoma. Together with the β1 or β7
integrin, the α4 integrin can act as a ligand for VCAM-1
and fibronectin. Animal models demonstrated, that the
metastatic capacity of melanoma cells enhanced through
α4β1 integrin interactions with VCAM-1 [93,94]. Further-
more, expression of the αvβ3 integrin has been associated
with the metastatic potential of tumor cells, but it seems
more to be involved in transmigration by interacting with
L1-CAM, than in the adhesion process [95]. Thus, as
already mentioned for the role of N-cadherin in tumor
cell rolling and diapedesis, the receptor involvement in
each step of the extravasation process in tumor cells is yet
not as clearly defined as in leukocytes.
In contrast to integrins, galectins are a group of adhesion
receptors that leukocytes share with tumor cells. In several
experimental systems galectin-3 expression in cancer cells
was associated with a metastatic phenotype [96]. During
the last twenty years it became evident, that an altered gly-
cosylation and exposure of glycoproteins by tumor cells
may facilitate their adhesion to endothelial galectins [78].
The Thomsen-Friedenreich antigen (TA) is expressed on
human breast and prostate carcinoma cell lines and serves
as a ligand for galectin-3 expressed on endothelium, lead-
ing to increased tumor cell adhesion [97-99]. TA is a sim-
ple mucin-type disaccharide with β-galactose as a terminal
sugar (Galβ1-3GalNAc). It is expressed on the surface of T
cell-lymphomas and most human carcinomas [100,101],
so far two surface molecules are known to represent TA:
MUC1 [102] and CD44v6 [103]. Furthermore, lysosomal-
membrane-associated glycoproteins (Lamps) 1 and 2 are
described as potential binding partners for galectin-3.
Lamps are rarely found on the plasma membrane of nor-
mal cells, but there is an increased surface expression in
tumor cells [104].
Clausse et al. observed that culture media, that were con-
ditioned by incubation with the prostate carcinoma cell
line PC-3, induced galectin-1 expression on the surface of
endothelial cells. This resulted in an increased attachment
of the tumor cells. The effect was inhibited by the addition
of a galectin-1-specific antibody [83]. This stands in clear
contrast to the above discussed role of galectin-1 in leuko-
cyte adhesion: here, adhesion was decreased in case of
galectin-1 expression.
Diapedesis
Leukocytes transmigrate through the endothelium with-
out irreversibly impairing its integrity. There are two
routes that the cells can use and it is not clear, to which
part each of these ways is involved in the diapedesis over-
all. The leukocytes can either move between the endothe-
lial cells, which is termed the paracellular or junctional
route, or they can migrate through an endothelial cell,
which is termed the transcellular route. Which way the
leukocytes take, obviously depends on several circum-
stances. Leukocytes subpopulations prefer different
routes, and the decision seems to depend on further fac-
tors, e.g. the duration of endothelium activation with
cytokines [105].
Paracellular route
When leukocytes transmigrate between two endothelial
cells, they have to pass tight junctions and adherens junc-
tions. Therefore, the connection between the endothelial
cells has to be temporarily abrogated and substituted by
the corresponding binding molecule on the leukocyte sur-
face. The platelet/endothelial cell adhesion molecule-1
(PECAM-1; CD31) is one of these molecules (Fig. 3). It is
a member of the Ig superfamily, homophilic binding, and
expressed on vascular endothelial cells as well as leuko-
cytes. It is one of the most important adhesion molecules
for the diapedesis of leukocytes. Blockade of this receptor
inhibits the transmigration of neutrophil granulocytes
[106], monocytes [106,107], and NK cells [108]. In con-
trast, CD31 is dispensable for the transmigration of lym-
phocytes [109]. However, there are reports showing that
PECAM-1 has to be regarded not only as an adhesion
receptor but also as a signalling receptor [110].Cell Communication and Signaling 2008, 6:10 http://www.biosignaling.com/content/6/1/10
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CD99 and the related molecule CD99L2 are further adhe-
sion molecules in the transmigration of leukocytes. CD99
is involved in monocyte, neutrophil granulocyte and lym-
phocyte diapedesis [111-113], but CD99L2 is not relevant
for lymphocyte diapedesis to inflamed tissue [112]. Like
PECAM-1, it is expressed on both leukocytes and endothe-
lial cells, and it has homophilic binding properties
[105,110].
A third group of receptors that have been identified to
play a role in the paracellular diapedesis of leukocytes are
the junctional adhesion molecules [114]. JAMs belong to
the Ig superfamily having two extracellular Ig domains. To
date, three members are known, designated as JAM-A to -
C (or JAM-1 to -3), whereas JAM-A is best characterized for
its role in leukocyte diapedesis. Initially, JAM-A has been
characterized as a homophilic adhesion receptor of tight
junctions on epithelial and endothelial cells [105,115].
Furthermore, JAM-A binds to LFA-1 (αLβ2 integrin) [116].
JAM-B binds to VLA-4 (α4β1 integrin), and JAM-C binds
to Mac-1, (αMβ2 integrin). All of the integrins are
expressed on leukocytes and consequently, endothelial
JAMs are supposed to play a crucial role in leukocyte dia-
pedesis [105,110,117]. It is worth of note, that JAM-C is
also expressed on leukocytes and interacts with JAM-B on
endothelial cells [118]. The endothelial selective adhesion
molecule (ESAM) is a receptor related to JAMs. However,
its expression is restricted to endothelial cells and acti-
vated platelets, no binding partner or counter-receptor on
leukocytes has been identified so far [110].
Transcellular diapedesis
As compared to the paracellular route, much less is known
about the transcellular diapedesis. This way of extravasa-
Transmigration of leukocytes through endothelium Figure 3
Transmigration of leukocytes through endothelium. Receptors involved in the paracellular or junctional route are 
shown on the left side, receptors involved in the transcellular route are shown on the right side. The endothelial cells are 
shown in green, the leukocytes in blue.Cell Communication and Signaling 2008, 6:10 http://www.biosignaling.com/content/6/1/10
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tion seems to be less used but much faster than the para-
cellular transmigration, whereas the part and kind of
leukocytes using this route varies obviously in depend-
ence on the type of endothelium [51,105]. ICAM-1 on the
endothelial cells is best characterized to play an important
role in the transcellular migration. ICAM-1 binds to the
integrin LFA-1 on leukocytes. ICAM-1 is redistributed to
caveolae-rich regions, where vesiculo-vacuolar organelles
form intracellular channels [51]. Besides ICAM-1,
PECAM-1 has been identified to be involved in this
extravasation route, and in general, the assumption has
been made that the same molecules that mediate paracel-
lular migration are mediators for the transcellular migra-
tion, too [117].
When the extravasating cells have successfully passed the
cellular barrier, they face a further hurdle. This is the base-
ment membrane, to which the leukocytes in fenestrated or
discontinuous endothelia, e.g. of the liver, can also attach
directly via integrin receptors to matric components. In
order to cross this barrier, leukocytes express matrix-met-
alloproteinases (MMPs), e.g. T lymphocytes express gela-
tinases A and B, which are two MMPs that digest the major
basal lamina constituents collagen types IV and V [119].
However, it is not clear, if MMPs only play a role in the
extravasation process or whether they contribute to the
migration of leukocytes through tissue [120].
Cancer cell diapedesis
In contrast to leukocytes, tumor cells are supposed not to
leave the endothelium intact after diapedesis. This is
understandable just from the bare size of the cells. Tumor
cells are much larger than leukocytes and it would be dif-
ficult to squeeze between endothelial cells without any
damage. One of the few reports on the mechanisms of
tumor cell diapedesis aims on the influence of N-cadherin
[40], which we have identified to mediate rolling of tumor
cells, too [28].
Consequently, a new model completely skips the transmi-
gration process: metastatic tumor cells attach to the
endothelium of pulmonary capillaries. Transmigrated
cells were cleared quickly by the immune cells of the lung,
whereas early tumor colonies were entirely attached to
endothelium on the intravascular side, as investigated by
intact organ epifluorescence microscopy in mice [121].
However, we have observed in an in vitro model, that T24
bladder carcinoma cells transmigrate through a monol-
ayer of human umbilical vein endothelial cells
(HUVECs). During transmigration, the endothelium is
irreversibly damaged [122], which is probably due to
induction of apoptosis by the loss of cell-cell contacts
[123]. Such an endothelial retraction is currently the
favored model for tumor cell diapedesis [33].
In conclusion, the first two steps of the extravasation of
tumor cells and leukocytes, rolling and adhesion, seem to
have similarities with regards to the mechanisms and
receptors involved. In contrast, the third step, the diaped-
esis, is fundamentally different between these two cell
types, whereas there is somehow a lack of knowledge with
regard to tumor cells. But it seems that the function of leu-
kocytes as guardians of the body is reflected in a cautious
manipulation of the endothelial cells. Tumor cells on the
contrary display a destructive behaviour.
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